Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al.|Annals of Oncology|2017

Cited by 90